Soluble urokinase-type plasminogen activator receptor (suPAR) is a risk indicator for eGFR loss in kidney transplant recipients

• Published in: Scientific reports 2021-02, Vol.11 (1), p.3713-3713, Article 3713
• Main Authors: Jehn, Ulrich, Schütte-Nütgen, Katharina, Henke, Ute, Pavenstädt, Hermann, Suwelack, Barbara, Reuter, Stefan
• Format: Article
• Language: English
• Subjects: 692/308; 692/4022; 692/53; Enzyme-linked immunosorbent assay; Epidermal growth factor receptors; Humanities and Social Sciences; Kidney diseases; Kidney transplantation; Kidney transplants; multidisciplinary; Science; Science (multidisciplinary); Transplants & implants; U-Plasminogen activator
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-021-83333-7

The prognostic significance of suPAR in various kidney diseases has recently been demonstrated. Its role in transplantation-specific outcomes is still largely unknown. Therefore, we prospectively investigated the prognostic relevance of suPAR in patients before and one year after kidney transplantation (KTx). We included 100 patients who had received a kidney transplantation between 2013 and 2015. The plasma concentration of suPAR was measured by ELISA assay. In recipients of living donations (LD), pre-transplant suPAR levels were significantly lower than those of recipients of deceased donations (DD). After KTx, suPAR levels significantly declined in LD and DD recipients, without a detectable difference between both groups any more. Higher suPAR levels in recipients one year after KTx were associated with a more severe eGFR loss in the following three years in multivariable cox-regression (n = 82, p = 0.021). suPAR-levels above 6212 pg/ml one year after KTx are associated with eGFR loss > 30%, which occurred almost twice as fast as in patients with suPAR ≤ 6212 pg/ml (p